Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
Fabrizio Bossa, Sonia Carparelli, Anna Latiano, Orazio Palmieri, Francesca Tavano, Anna Panza, Maria Pastore, Antonio Marseglia, Mario D’Altilia, Tiziana Latiano, Giuseppe Corritore, Giuseppina Martino, Marianna Nardella, María Guerra, Fulvia Terracciano, Michele Sacco, Francesco Perri, Angelo Andriulli
Topics & Concepts
MedicineInternal medicineInfliximabAdalimumabInflammatory bowel diseaseUlcerative colitisUstekinumabVedolizumabGolimumabDiseaseGastroenterologyImmunologyInflammatory Bowel DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies